Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRG | P23470 | 4/20 | 0.70 |
| ▸ | PTPRC | P08575 | 4/20 | 0.61 |
| ▸ | AR | P10275 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | PRNP | P04156 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11565647 | 0.86 | AR (0.64) | PTPRGPTPRCARMRGPRX4RAB9A | |
| SCHEMBL1901284 | 0.84 | PTPRG (0.67) | PTPRGPTPRCRAB9ANPC1CYP1A2 | |
| SCHEMBL4741951 | 0.82 | PTPRG (0.62) | PTPRGRAB9ACYP1A2KMT2AMEN1 | |
| SCHEMBL11822185 | 0.81 | PTPRC (0.55) | PTPRGPTPRCARMRGPRX4CYP1A2 | |
| SCHEMBL28801720 | 0.80 | PTPRG (0.58) | PTPRGPTPRCARMRGPRX4RAB9A | |
| SCHEMBL2124636 | 0.80 | PTPRC (0.54) | PTPRGPTPRCARMRGPRX4CYP1A2 | |
| SCHEMBL11817360 | 0.78 | AR (0.57) | PTPRGPTPRCARMRGPRX4CYP1A2 | |
| SCHEMBL9716018 | 0.78 | PTPRG (0.68) | PTPRGPTPRCRAB9ANPC1CYP1A2 | |
| SCHEMBL7374000 | 0.77 | TSHR (0.57) | MRGPRX4KMT2AMEN1 | |
| SCHEMBL11817253 | 0.77 | PTPRG (0.52) | PTPRGPTPRCARMRGPRX4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | PTPRG 2835/4885PTPRC 3644/4885AR 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.